Ticker Details
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
IPO Date:	May 11, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.49B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.17 | 2.68%
Avg Daily Range (30 D):	$0.42 | 3.47%
Avg Daily Range (90 D):	$0.46 | 4.02%

Institutional Daily Volume
Avg Daily Volume:	.88M
Avg Daily Volume (30 D):	2.24M
Avg Daily Volume (90 D):	3.17M

Trade Size
Avg Trade Size (Sh.):	82
Avg Trade Size (Sh.) (30 D):	87
Avg Trade Size (Sh.) (90 D):	102

Institutional Trades
Total Institutional Trades:	5,565
Avg Institutional Trade:	$3.06M
Avg Institutional Trade (30 D):	$1.98M
Avg Institutional Trade (90 D):	$2.39M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.9M
Avg Closing Trade (30 D):	$3.19M
Avg Closing Trade (90 D):	$3.85M
Avg Closing Volume:	122.99K

News

Jan 15, 2026 @ 2:48 AM Biohaven (BHVN) Stock Is Trending Overnight â€â... Source: Mohd Haider

Dec 26, 2025 @ 2:26 PM Stock Market Today: Dow Jones, S&P 500, Nasdaq Fut... Source: Rishabh Mishra

Dec 2, 2025 @ 6:00 PM Migraine Clinical Trial Pipeline Expands as 30+ Co... Source: Delveinsight

Nov 19, 2025 @ 10:15 PM Biohaven's Chief Accounting Officer Scooped Up 17,... Source: Robert Izquierdo

Oct 15, 2025 @ 11:00 AM Bexorg Raises $42.5M to Transform CNS Drug Develop... Source: Zvonimir Vrselja, M.D., Ph.D.

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-1.64	$-1.94	$-2.17
Diluted EPS	$-1.64	$-1.94	$-2.17
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-173.44M	$-198.15M	$-221.68M
Operating Income / Loss	$-169.38M	$-211.7M	$-221.56M
Cost of Revenue
Net Cash Flow	$19.39M	$66.31M	$.15M
PE Ratio